**Oric Pharmaceuticals Focuses on Lead Programs Amidst Financial Realignment**
Oric Pharmaceuticals, a biopharmaceutical company specializing in cancer resistance, reported its financial results for the year ended December 31, 2025, showcasing a net loss of $129.5 million, compared to a net loss of $127.8 million in 2024. The company's accumulated deficit reached $692.2 million. Research and development expenses totaled $109.8 million, a decrease from $114.1 million in the previous year, attributed to lower rinzimetostat drug manufacturing costs and reduced spending on discontinued programs, partially offset by increased personnel costs and advancement of enozertinib. General and administrative expenses rose to $33.2 million from $28.8 million, driven by higher personnel costs and professional service fees.
The company's strategic shift towards prioritizing its lead clinical programs, rinzimetostat and enozertinib, led to a significant reduction in preclinical research activities, including the elimination of its discovery research group. This realignment resulted in a one-time cost of approximately $1.9 million related to termination benefits. As of December 31, 2025, Oric Pharmaceuticals held $392.3 million in cash, cash equivalents, and investments. The company anticipates that these funds will sustain operations into the second half of 2028.
Key operational developments for rinzimetostat include the completion of the dose exploration portion of a Phase 1b trial and the selection of provisional recommended Phase 2 doses (RP2Ds) for combination therapy with darolutamide and apalutamide. Phase 1b dose exploration data demonstrated PSA responses and circulating tumor DNA (ctDNA) reductions across all rinzimetostat dose levels. The company expects to report dose optimization data in the first quarter of 2026 and initiate a global Phase 3 registrational trial in metastatic castration-resistant prostate cancer (mCRPC) in the first half of 2026.
Enozertinib's development saw the reporting of additional Phase 1b data at the 2025 ESMO Asia Congress, showcasing systemic and intracranial activity in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 and EGFR atypical mutations. Based on these data, 80 mg QD oral enozertinib has been selected as the monotherapy dose for potential Phase 3 development. A Phase 1b trial evaluating enozertinib in combination with amivantamab was initiated in the first quarter of 2025, with data expected in the second half of 2026. The company had 104 full-time employees as of December 31, 2025, with 76 engaged in research and development activities.
About Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals is a biopharmaceutical company focused on developing therapies that overcome resistance in cancer. Its pipeline includes targeted treatments for hormone-dependent cancers, precision oncology, and tumor dependencies, with a focus on resistant solid tumors like lung and prostate cancers. The company leverages biomarker-driven approaches, internal discovery capabilities, and strategic collaborations to deliver innovative, targeted cancer therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.